Aurélie Du-Thanh
Aurélie Du-Thanh is an expert in Dermatology at University Hospital of Montpellier (France). As of October 2026, ScienceLeadR ranks Aurélie Du-Thanh in the top 1% of experts worldwide for Hypersensitivity and Skin Diseases, Vascular. Aurélie Du-Thanh has authored 241 publications, the most recent in 2026, and is an investigator in 13 clinical trials, 6 of them ongoing. SLR score: 839 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2006 - 2026
Number : 241
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Berotralstat Tolerability and Effectiveness in Hereditary Angioedema: Berolife Study Results. PMID 42603305 — pain, angioedemas, hereditary, therapeutics, angioedema, abdominal pain | Clin Transl Allergy | 2026 | 0 |
| Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial. PMID 41865747 — skin, safety, pain, pharmaceutical preparations, angioedemas, hereditary, drug-related side effects and adverse reactions, capsules, bradykinin, therapeutics, angioedema, hematologic diseases | Lancet Haematol | 2026 | 0 |
| Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema. PMID 41705342 — skin, dermatitis, hypersensitivity, eczema, immunity, therapeutics, psoriasis, dermatitis, atopic, dermatitis, contact | Allergy | 2026 | 0 |
| The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. PMID 41649409 — cells, hypersensitivity, urticaria, classification, work, diagnosis, therapeutics, angioedema, mast cells | Allergy | 2026 | 2 |
| Diagnostic Delay in Patients With Chronic Urticaria: Results From the Chronic Urticaria Registry (CURE). PMID 41532284 — registries, chronic urticaria, hypersensitivity, urticaria, diagnosis, chronic inducible urticaria | Clin Exp Allergy | 2026 | 1 |
Clinical Studies 13
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
6 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A 52 week multi center randomized double blind placebo controlled basket study with an open label extension to investigate the efficacy safety and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1 antihistamines 2023-505739-12-01 — histamine antagonists, safety, urticaria, multiple chronic conditions, chronic inducible urticaria | Phase 3 | Active not recruiting | 2024 |
| STOP HAE A Phase 3 Study of ADX 324 in HAE 2025-521352-38-00 — rna, small interfering, angioedemas, hereditary, prekallikrein, therapeutics, angioedema | Phase 3 | Recruiting | 2026 |
| Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate to Severe Atopic Dermatitis 2023-508235-31-00 — safety, dermatitis, signs and symptoms, adolescent, therapeutics, dermatitis, atopic | Phase 3 | Active not recruiting | 2024 |
| A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial 2025-524078-40-00 — urticaria, multiple chronic conditions, therapeutics | Phase 3 | Recruiting | 2026 |
| A 12 week randomized participant and investigator blinded placebo controlled exploratory study in adult participants with Chronic Urticaria to assess the efficacy and safety and explore the Mechanism of Action of remibrutinib (LOU064) 2024-516355-41-00 — chronic urticaria, safety, urticaria, chronic inducible urticaria | Phase 2 | Recruiting | 2025 |
LeadR Networks
Main global connection map